Thermo Fisher invests to boost production of cell culture media

Thermo Fisher Scientific Greenville, NC site
Among other investments this year, Thermo Fisher Scientific opened a virtual reality training center at its site in Greenville, North Carolina. (Thermo Fisher Scientific)

Last month, Thermo Fisher Scientific said it was investing more than $250 million in its operations in the U.S. and Europe as well as in India, Argentina and China. Now, add the U.K. to the list. 

The company today said it will invest nearly $24 million in its biologics site at Inchinnan, Scotland, to boost its ability to manufacture cell culture media. It said it expects to complete the work in 2021. 

“This investment will expand capabilities and expertise at our existing cell culture manufacturing center of excellence in the UK to meet growing customer demand," Cory Stevenson, president of Thermo Fisher's bioproduction business, said in a statement. 

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Last month, the Waltham, Massachusetts-based operation said its 2019 capital expenditures would reach $270 million with investments in its fill-finish operations, distribution in Asia, South America and India and a virtual reality training center in Greenville, North Carolina. 

RELATED: Thermo Fisher shoulders into gene therapy manufacturing with $1.7B deal for Brammer

The company also paid $110 million for a GlaxoSmithKline API plant in Ireland, and the CDMO unit will open a viral vector plant later this year in the U.S. 

The viral vector facility in Lexington, Massachusetts, is part of the $1.7 billion cash deal Thermo Fisher pulled off earlier this year for Brammer Bio, which gave Thermo Fisher an operation to play in the growing field for gene-modified cell therapies and in vivo gene therapies. The 50,000-square-foot plant will have 200 employees.

Other contractors are also building their capabilities in cell and gene therapies. Catalent Monday said it has launched a new technology it says can increase cell line productivity. 

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.